Broad Institute, MD Anderson Cancer Center designated as Genome Characterization Centers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BROAD INSTITUTE and MD ANDERSON CANCER CENTER were designated the Genome Characterization Centers in a five-year project supported by the NCI to characterize the genomic changes found in tumors.

GCC’s funding comes via a research subcontract with Leidos Biomedical Research Inc., operations and technical support contractor for NCI’s Frederick National Laboratory for Cancer Research.

The centers will provide Whole Genome, Whole Exome and RNA sequencing to support three main project areas:

  • The Exceptional Responders Initiative aimed at discovering and understanding the molecular events involved in extraordinary individual responses to otherwise unsuccessful targeted experimental cancer therapies.
  • The ALCHEMIST Project (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) aimed at providing molecular data to support biomarker classification and genomic characterization of lung cancer patients enrolled in clinical trials.
  • The Cancer Driver Discovery Project aimed at providing additional statistical power to discover driver mutations in lung, colon and ovarian cancer.

The project was funded under Contract No. HHSN261200800001E.

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login